Efficacy and Safety of Darunavir and Lopinavir in Treating HIV in Pediatric and Adolescent Populations: A Systematic Review - Takeaways - MDSpire

Efficacy and Safety of Darunavir and Lopinavir in Treating HIV in Pediatric and Adolescent Populations: A Systematic Review

  • By

  • John O’Rourke

  • Claire L. Townsend

  • Edith Milanzi

  • Hannah Castro

  • Intira Jeannie Collins

  • Ali Judd

  • Julie Jesson

  • Valériane Leroy

  • Martina Penazzato

  • Marissa Vicari

  • Françoise Renaud

  • April 3, 2026

  • 0 min

Share

  • 1

    An estimated 2.58 million children and adolescents were living with HIV in 2022, highlighting the need for effective treatment options.

  • 2

    Darunavir and lopinavir are recommended protease inhibitors for treating HIV in pediatric populations, with specific formulations for different age groups.

  • 3

    WHO guidelines suggest using ritonavir-boosted darunavir as a second-line therapy if dolutegravir fails, and lopinavir as a first-line alternative.

  • 4

    The systematic review aims to summarize the efficacy and safety of darunavir and lopinavir in children and adolescents to inform future WHO recommendations.

  • 5

    Eligibility criteria for the review included studies assessing the effectiveness and safety of darunavir or lopinavir in populations aged 0-19 years.

Original Source(s)

Efficacy and Safety of Darunavir and Lopinavir in Treating HIV in Pediatric and Adolescent Populations: A Systematic Review

  • by John O’Rourke, Claire L. Townsend, Edith Milanzi, Hannah Castro, Intira Jeannie Collins, Ali Judd, Julie Jesson, Valériane Leroy, Martina Penazzato, Marissa Vicari, Françoise Renaud

  • April 3, 2026

Related Content

Identification of clinical phenotypes and prediction model for the mixed-infection phenotype of pediatric community-acquired pneumonia based on unsupervised machine learning

FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.